Fig. 7
From: Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus
Neuroblastoma lines with high levels of active ALK also have high levels of pY-GSK3. a Western blotting of neuroblastoma lines reveals levels of pY-GSK3 correlates with levels of ALK-pY1507 (IMR5, Kelly, Be(2)C, IMR32, SH-SY-5Y, SK-N-SH). Cell lines with low or no ALK-pY1507 (SK-N-AS, LS, CHP-212) have correspondingly low levels of pY-GSK3. b Western blotting showing that only Kelly cells have high levels of ALK when compared to mouse embryonic fibroblasts (MEFs) and LS neuroblastoma cells. c Western blotting analysis reveals that, in Kelly cell line, ALK inhibition with NVP-TAE, results in gradual loss pYGSK-3α and pYGSK-3β, are significantly reduced after 24 h treatment with NVP-TAE, GSK3 inhibition, using BIO or CHIR, leads to a reduced expression of pY-GSK3, more predominantly is pY-GSK3α isoform. Some loss of ALK is also seen in NVP treatments. Treatments used were 1.5 µM crizotinib, 1.5 µM AZD-3463, 1 µM NVP-TAE-684 (NVP1), 2 µM NVP-TAE-684 (NVP2), 0.5 μM BIO and 1.0 μM CHIR99021
